Experience key to appointment of chairman at Elan pharmaceuticals
ATHLONE-based pharmaceutical company Elan has named Robert Ingram (right), a former top executive at GlaxoSmithKline, as chairman.
The 67-year-old was a general partner of venture capital firm Hatteras that invests in early stage life science companies, and previously served as vice chairman of pharmaceuticals at GlaxoSmithKline.
Mr Ingram is a busy man for his age and currently serves on the boards of directors of Allergan, Cree, Edwards Lifesciences, OSI Pharmaceuticals and Valeant.
He follows Kyran McLaughlin, who indicated earlier year his intention to step down from the post.
Activist investors including Denmark-based Ib Sonderby have been pressing Elan to appoint board members with strong industry experience. Mr Ingram will assume the chairmanship at the pharma's next board meeting on January 26.